MedTrace Logo

Role of Proton Pump Inhibitors on the Postoperative Course Following Pancreaticoduodenectomy

NCT05251233 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2025-05-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to prospectively determine the effects of administering proton pump inhibitors (PPIs) following pancreaticoduodenectomy on postoperative outcomes. The findings of this study will help in avoiding the widespread use of PPIs during the immediate postoperative period following pancreatic surgery.

Conditions

  • Pancreatic Cancer
  • Pancreas Cancer
  • Ampullary Cancer
  • Pancreas Neuroendocrine Tumor
  • Pancreatitis
  • Distal Extrahepatic Cholangiocarcinoma
  • Duodenal Cancer

Interventions

DRUG

Placebo

Placebo capsules contain pharmaceutical-grade lactose monohydrate NF, a naturally occurring disaccharide of galactose bound to glucose.

DRUG

Pantoprazole

The study will use commercial supply.

Sponsors & Collaborators

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Natasha Leigh-Matijakovich, M.D. · Washington University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-21
Primary Completion
2024-06-29
Completion
2024-06-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05251233 on ClinicalTrials.gov